These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23347316)

  • 61. Doxorubicin/paclitaxel combination does not expose breast cancer patients to excessive cardiac risk.
    Oncology (Williston Park); 2001 Jul; 15(7):830. PubMed ID: 11499684
    [No Abstract]   [Full Text] [Related]  

  • 62. [Safety evaluation of paclitaxel injection NK in adjuvant therapy for breast cancer].
    Takahara S; Yamamoto H; Tokushima Y; Shiba E
    Gan To Kagaku Ryoho; 2009 Nov; 36(11):1851-6. PubMed ID: 19920387
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Scleroderma in association with the use of docetaxel (taxotere) for breast cancer.
    Hassett G; Harnett P; Manolios N
    Clin Exp Rheumatol; 2001; 19(2):197-200. PubMed ID: 11326485
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Study finds that hormone status may predict chemotherapy's effectiveness on breast cancer.
    McBride D
    ONS Connect; 2008 Jan; 23(1):25. PubMed ID: 18284079
    [No Abstract]   [Full Text] [Related]  

  • 65. Advances in taxane therapy for metastatic breast cancer.
    ONS News; 2004; 19(9 Suppl):75-6. PubMed ID: 15478598
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intestinal side-effects of docetaxel/vinorelbine combination.
    de Matteis A; Nuzzo F; Rossi E; Landi G; Perrone F
    Lancet; 2000 Mar; 355(9209):1098-9. PubMed ID: 10744113
    [No Abstract]   [Full Text] [Related]  

  • 67. New approach reduces side effects of high-dose chemotherapy for breast cancer.
    Oncology (Williston Park); 1999 Sep; 13(9):1316. PubMed ID: 10509326
    [No Abstract]   [Full Text] [Related]  

  • 68. [Progress and perspectives in palliative therapy of breast carcinoma].
    Verlag GT
    Dtsch Med Wochenschr; 1996 Dec; 121(49 Suppl):1-8. PubMed ID: 8983911
    [No Abstract]   [Full Text] [Related]  

  • 69. Nail alterations secondary to pactitaxel [corrected] therapy.
    Almagro M; Pozo JD; Garcia J; Vasquez A; Fonseca E
    Eur J Dermatol; 2000 Mar; 10(2):146-7. PubMed ID: 10694317
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Paclitaxel-induced cardiotoxicity. An ultrastructural study.
    Shek TW; Luk IS; Ma L; Cheung KL
    Arch Pathol Lab Med; 1996 Jan; 120(1):89-91. PubMed ID: 8554453
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Radiation recall dermatitis induced by erlotinib.
    Dauendorffer JN; Dupuy A
    J Am Acad Dermatol; 2009 Dec; 61(6):1086. PubMed ID: 19925938
    [No Abstract]   [Full Text] [Related]  

  • 72. Nab-paclitaxel-induced cystoid macular edema in a patient with pre-existing optic neuropathy.
    Park E; Goldberg NR; Adams S
    Anticancer Drugs; 2016 Jul; 27(6):580-4. PubMed ID: 26982237
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Efficacy and tolerability of controlled-release oxycodone against nab-paclitaxel-induced musculoskeletal pain in breast cancer patients].
    Inoue K; Ohkubo F; Nagai S; Tsuboi M; Kubo K; Kurozumi K; Hayashi Y; Matsumoto H; Takei H
    Gan To Kagaku Ryoho; 2013 Aug; 40(8):1021-5. PubMed ID: 23986044
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Quinolone-induced radiation recall dermatitis in breast cancer patient.
    Rafiroiu S; Vassil A; Valente SA
    Breast J; 2020 Jul; 26(7):1407-1408. PubMed ID: 31999006
    [No Abstract]   [Full Text] [Related]  

  • 75. Paclitaxel package insert.
    Solimando DA
    Cancer Invest; 1997; 15(5):503. PubMed ID: 9340126
    [No Abstract]   [Full Text] [Related]  

  • 76. Manufacturer's labeling for paclitaxel.
    Hill RJ
    Cancer Invest; 1996; 14(6):644. PubMed ID: 8951370
    [No Abstract]   [Full Text] [Related]  

  • 77. Paclitaxel treatment article misleading.
    Davutoglu V; Soydinc S
    J Natl Med Assoc; 2003 Dec; 95(12):1231-3. PubMed ID: 14717483
    [No Abstract]   [Full Text] [Related]  

  • 78. Radiation recall dermatitis induced by ibuprofen.
    Zhang LW; Wu J; Zheng L; Chen T
    An Bras Dermatol; 2023; 98(4):554-556. PubMed ID: 36967273
    [No Abstract]   [Full Text] [Related]  

  • 79. Isoscartopic Response: Another Facet of the Immunocompromised Cutaneous District.
    Caccavale S; La Montagna M; Caccavale T
    Indian J Dermatol; 2016; 61(2):219-20. PubMed ID: 27057029
    [No Abstract]   [Full Text] [Related]  

  • 80. Recall phenomena: another facet of the immunocompromised district.
    Ruocco V; Ruocco E; Brunetti G
    Int J Dermatol; 2013 Feb; 52(2):252-3. PubMed ID: 23347316
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.